16 Mar 2017
Lonza Reveals New Portfolio of High-Quality Human and Animal Hepatocytes for ADME-Tox Testing

Cologne, Germany / Basel, Switzerland, 16 March 2017 – Lonza now offers a comprehensive portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing, further strengthening its position as a leader in cell discovery. This expansion of Lonza's primary cells range is the result of last year's acquisition of renowned hepatocyte provider, Triangle Research Laboratories (TRL). By combining TRL's expertise with Lonza's quality control, large production capacity and scientific support, Lonza can now provide a source of high-quality hepatocytes for in-vitro drug metabolism and pharmacokinetic studies or for vital research into diseases such as Malaria and Hepatitis B.

Lonza's new range of ADME-Tox products includes both fresh and cryopreserved human and animal hepatocytes, supporting researchers with a variety of in-vitro applications, including studies into drug metabolism and toxicity, drug-transporter activity and drug-drug interactions. The new hepatocyte portfolio also features hepatic non-parenchymal cells, such as stellate and Kupffer cells, which can improve the translatability of in-vitro toxicity testing and pharmacokinetics research to clinical trials.

Lonza's hepatocytes are pre-qualified for a variety of different applications, which helps to reduce time and money spent evaluating cells for specific experiments within the laboratory. The new range also includes supporting ADME-Tox products such as specialized hepatocyte media and cell culture systems, helping to optimize hepatocyte culture performance for in-vitro drug screening or for research into drug-induced liver injury and other important liver diseases.

“With many conclusions regarding the pharmacokinetics and safety of a drug candidate being drawn from the results of in-vitro studies on human hepatocytes, researchers need a source of hepatocytes they can rely on,” said Maureen Bunger, Product Manager for ADME-Tox Solutions at Lonza. “By blending the extensive expertise of Lonza and TRL, our new hepatocyte portfolio will address the needs of the scientific community, offering hepatocytes that produce consistent and reliable results for ADME-Tox testing and for research into liver-associated diseases.”

For more information about Lonza's hepatocyte portfolio, please visit: https://www.lonza.com/products-services/bio-research/adme-tox.aspx